Aerie Pharmaceuticals Inc logo

AERI - Aerie Pharmaceuticals Inc News Story

$11.73 0.3  2.6%

Last Trade - 8:25pm

Sector
Healthcare
Size
Mid Cap
Market Cap £413.4m
Enterprise Value £380.1m
Revenue £63.4m
Position in Universe 2874th / 6412

BRIEF-Aerie Pharmaceuticals Reports Positive Topline Results For Ar-1105 Phase 2 Clinical Trial In Patients With Macular Edema Due To Retinal Vein Occlusion

Mon 27th July, 2020 11:40am
July 27 (Reuters) - Aerie Pharmaceuticals Inc  AERI.O :
    * AERIE PHARMACEUTICALS REPORTS POSITIVE TOPLINE RESULTS FOR
AR-1105 (DEXAMETHASONE INTRAVITREAL IMPLANT) PHASE 2 CLINICAL
TRIAL IN PATIENTS WITH MACULAR EDEMA DUE TO RETINAL VEIN
OCCLUSION
    * AERIE PHARMACEUTICALS INC - BOTH FORMULATIONS, CF-1 AND
CF-2,
WERE WELL TOLERATED WITH NO UNEXPECTED SAFETY FINDINGS

Source text for Eikon:  ID:nBw7gjBVqa 
Further company coverage:  AERI.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.